Literature DB >> 18063510

Chromosomal gain of 3q and loss of 11q often associated with nodal metastasis in early stage cervical squamous cell carcinoma.

Kuo-Feng Huang1, Wen-Ying Lee, Soon-Cen Huang, Yue-Shan Lin, Chieh-Yi Kang, Chiou-Ping Liou, Ching-Cherng Tzeng.   

Abstract

BACKGROUND/
PURPOSE: Cervical cancer remains a health problem among women worldwide. Delineation of genetic changes is critical to understanding the molecular basis of tumor progression, as well as for identifying genetic markers for early identification of patients at high risk for a poor outcome.
METHODS: To provide comparative genomic hybridization data for cervical squamous cell carcinoma in Taiwan, and to gain further insight into genetic markers associated with lymph node metastasis of this disease, we performed comparative genomic hybridization analysis of 30 consecutive cases of cervical squamous cell carcinoma (24 stage IB and 6 stage IIB).
RESULTS: The results disclosed that higher staged tumors or those with lymph node metastasis had more chromosomal imbalances. The commonly recurrent chromosomal imbalances were gains of 3q (46.7%), 1q (36.7%) and 8q (20.0%) and losses of 11q (36.7%), 3p (33.3%), 6q (23.3%), and 2q (20.0%). The frequencies of these chromosomal imbalances in stage IB and IIB tumors did not differ significantly. However, when compared with tumors without lymph node metastasis, the loss of 11q14-q22 (5/9 vs. 3/21, p = 0.019) and gains of 3q11-q22 and 3q26-qter (6/9 vs. 5/21, p = 0.026) were significantly more prevalent in tumors with lymph node metastasis.
CONCLUSION: The results suggest that certain tumor-associated genes residing on 3q and 11q warrant further investigation to elucidate their role in the progression of this disease.

Entities:  

Mesh:

Year:  2007        PMID: 18063510     DOI: 10.1016/S0929-6646(08)60059-5

Source DB:  PubMed          Journal:  J Formos Med Assoc        ISSN: 0929-6646            Impact factor:   3.282


  10 in total

1.  Fluorescence in situ hybridization markers for prediction of cervical lymph node metastases.

Authors:  Darawalee Wangsa; Kerstin Heselmeyer-Haddad; Patricia Ried; Elina Eriksson; Alejandro A Schäffer; Larry E Morrison; Juhua Luo; Gert Auer; Eva Munck-Wikland; Thomas Ried; Elisabeth Avall Lundqvist
Journal:  Am J Pathol       Date:  2009-11-05       Impact factor: 4.307

2.  The significant diagnostic value of human telomerase RNA component (hTERC) gene detection in high-grade cervical lesions and invasive cancer.

Authors:  Xiaobin Wang; Jia Liu; Hong Xi; Liping Cai
Journal:  Tumour Biol       Date:  2014-04-16

3.  Genome-wide screening of DNA copy number alterations in cervical carcinoma patients with CGH+SNP microarrays and HPV-FISH.

Authors:  Petr Kuglik; Jan Smetana; Vladimira Vallova; Lucie Moukova; Katerina Kasikova; Michaela Cvanova; Lucie Brozova
Journal:  Int J Clin Exp Pathol       Date:  2014-07-15

4.  Molecular biology of gynecological cancer.

Authors:  Kenzo Sonoda
Journal:  Oncol Lett       Date:  2015-11-05       Impact factor: 2.967

5.  Gene network reconstruction reveals cell cycle and antiviral genes as major drivers of cervical cancer.

Authors:  Karina L Mine; Natalia Shulzhenko; Anatoly Yambartsev; Mark Rochman; Gerdine F O Sanson; Malin Lando; Sudhir Varma; Jeff Skinner; Natalia Volfovsky; Tao Deng; Sylvia M F Brenna; Carmen R N Carvalho; Julisa C L Ribalta; Michael Bustin; Polly Matzinger; Ismael D C G Silva; Heidi Lyng; Maria Gerbase-DeLima; Andrey Morgun
Journal:  Nat Commun       Date:  2013       Impact factor: 14.919

Review 6.  Gynecologic Cancer, Cancer Stem Cells, and Possible Targeted Therapies.

Authors:  Vahideh Keyvani; Espanta Riahi; Meysam Yousefi; Seyed-Alireza Esmaeili; Rana Shafabakhsh; Amin Moradi Hasan-Abad; Maryam Mahjoubin-Tehran; Michael R Hamblin; Samaneh Mollazadeh; Hamed Mirzaei
Journal:  Front Pharmacol       Date:  2022-02-16       Impact factor: 5.810

7.  3q26 amplification is an effective negative triage test for LSIL: a historical prospective study.

Authors:  Erica R Heitmann; Kamani M Lankachandra; Jeff Wall; George D Harris; Hollie J McKinney; G Reza Jalali; Yogita Verma; Eric Kershnar; Michael W Kilpatrick; Petros Tsipouras; Diane M Harper
Journal:  PLoS One       Date:  2012-07-06       Impact factor: 3.240

8.  An Optimization-Driven Analysis Pipeline to Uncover Biomarkers and Signaling Paths: Cervix Cancer.

Authors:  Enery Lorenzo; Katia Camacho-Caceres; Alexander J Ropelewski; Juan Rosas; Michael Ortiz-Mojer; Lynn Perez-Marty; Juan Irizarry; Valerie Gonzalez; Jesús A Rodríguez; Mauricio Cabrera-Rios; Clara Isaza
Journal:  Microarrays (Basel)       Date:  2015-06

9.  Loss of heterozygosity and copy number alterations in flow-sorted bulky cervical cancer.

Authors:  Sabrina A H M van den Tillaart; Wim E Corver; Dina Ruano Neto; Natalja T ter Haar; Jelle J Goeman; J Baptist M Z Trimbos; Gertjan J Fleuren; Jan Oosting
Journal:  PLoS One       Date:  2013-07-09       Impact factor: 3.240

10.  Identification of novel genomic aberrations in AML-M5 in a level of array CGH.

Authors:  Rui Zhang; Ji-Yun Lee; Xianfu Wang; Weihong Xu; Xiaoxia Hu; Xianglan Lu; Yimeng Niu; Rurong Tang; Shibo Li; Yan Li
Journal:  PLoS One       Date:  2014-04-11       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.